The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)
Abstract
INTRODUCTION The efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ETI) have been established in prospective clinical trials. Liver function test elevations were observed in a greater proportion of patients receiving ETI compared with placebo; however, the relatively small number of patients and short duration of study preclude detection of rare but clinically significant associations with drug-induced liver injury (DILI). To address this gap, we assessed the real-world risk of DILI associated with ETI through data mining of the FDA adverse event reporting system (FAERS). METHODS Disproportionality analyses were conducted on FAERS data from the fourth quarter of 2019 through the third quarter of 2022. Comparative patient demographics, onset time and outcomes for ETI-DILI were also obtained. RESULTS 452 reports of DILI associated with ETI were found, representing 2.1 % of all adverse event reports for ETI. All disproportionality measures were significant for ETI-DILI at p < 0.05; the reporting odds ratio (ROR) (2.82) was comparable to that of drugs classified by FDA as "Most-DILI concern". The most notable demographic finding was a male majority (5:4 male to female ratio) for ETI-DILI compared to a female majority (4:5 male to female ratio) for non ETI-DILI. Median ETI-DILI onset time was 50.5 days, and hospitalization was the second most common complication. CONCLUSION Using FAERS data, ETI was found to be disproportionately associated with DILI. Future research is needed to investigate the hepatotoxic mechanisms and assess potential mitigation strategies for ETI-induced hepatotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In post-marketing surveillance studies of triple therapy, case reports of clinically significant liver injury have been reported at several weeks to months of treatment that improved with drug discontinuation.”
From The contemporary epidemiology, causes, and management of drug-induced liver injury (2026) · cites this paper as [70]
In the citing paper
“However, instances of liver failure, liver transplantation, and death have also been reported. 70”
From The contemporary epidemiology, causes, and management of drug-induced liver injury (2026) · cites this paper as [70]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198
Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32597-8 · Cited by 1,414
Chen, M., Suzuki, A., Thakkar, S., Yu, K., Hu, C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.015 · Cited by 398
Research works printed but not linked: 23
- Sutharsan, 2022, Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial, Lancet Respir Med, 10, 267, 10.1016/S2213-2600(21)00454-9 · DOI
- Barry, 2021, Triple therapy for Cystic Fibrosis, N Engl J Med, 385, 815, 10.1056/NEJMoa2100665 · DOI · Paper page
- Zemanick, 2021, A phase 3 open-label study of Elexacaftor/Tezacaftor/Ivacaftor in children 6 through 11 years of age with Cystic Fibrosis and at least one, Am J Respir Crit Care Med, 203, 1522, 10.1164/rccm.202102-0509OC · DOI · Paper page
- Mall, 2022, Efficacy and safety of Elexacaftor/Tezacaftor/Ivacaftor in children 6 through 11 years of age with Cystic Fibrosis Heterozygous for, Am J Respir Crit Care Med, 206, 1361, 10.1164/rccm.202202-0392OC · DOI
- Tewkesbury, 2023, Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis centre, J Cyst Fibros, 22, 256, 10.1016/j.jcf.2023.01.007 · DOI
- Lowry, 2022, Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor, J Cyst Fibros, 21, e99, 10.1016/j.jcf.2021.07.001 · doi:10.1016/j.jcf.2021.07.001
- Bocci, 2022, State of the Art and uses for the biopharmaceutics drug disposition classification system (BDDCS): new additions, revisions, and citation references, AAPS J, 24, 37, 10.1208/s12248-022-00687-0 · DOI
- Chan, 2017, Evaluation of DILI predictive hypotheses in early drug development, Chem Res Toxicol, 30, 1017, 10.1021/acs.chemrestox.7b00025 · DOI
- Salehi, 2021, Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio), Respir Med Case Rep, 34
- Smith, 2022, Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis, J Cyst Fibros, 21, e8, 10.1016/j.jcf.2021.05.008 · doi:10.1016/j.jcf.2021.05.008
- Berthold MR, Cebron N, Dill F, Gabriel TR, Kötter T, Meinl T, et al., editors. KNIME: The konstanz information miner2008; Berlin, Heidelberg: Springer Berlin Heidelberg. · DOI · Paper page
- Khaleel, 2022, A standardized dataset of a spontaneous adverse event reporting system, Healthcare (Basel), 10
- Zhou, 2022, Antifungal drugs and drug-induced liver injury: a real-world study leveraging the FDA adverse event reporting system database, Front Pharmacol, 13, 10.3389/fphar.2022.1044744 · DOI
- Raschi, 2022, Liver Injury with Nintedanib: a Pharmacovigilance-pharmacokinetic appraisal, Pharmaceuticals (Basel)., 15, 10.3390/ph15050645 · DOI
- Evans, 2001, Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports, Pharmacoepidemiol Drug Saf, 10, 483, 10.1002/pds.677 · DOI · Paper page
- Amacher, 2014, Female gender as a susceptibility factor for drug-induced liver injury, Hum Exp Toxicol, 33, 928, 10.1177/0960327113512860 · DOI
- Rana, 2021, Hepatotoxicity reports in the FDA adverse event reporting system database: a comparison of drugs that cause injury, Acta Pharm Sin B, 11, 3857, 10.1016/j.apsb.2021.05.028 · DOI
- McEuen, 2017, Associations of drug lipophilicity and extent of metabolism with drug-induced liver injury, Int J Mol Sci, 18, 10.3390/ijms18071335 · DOI · Paper page
- Pannu, 2023, Adverse events of SARS-CoV-2 therapy: a pharmacovigilance study of the FAERS database, Ann Pharmacother
- Lu, 2020, Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system, Int J Clin Pharm, 42, 1364, 10.1007/s11096-020-01037-w · doi:10.1007/s11096-020-01037-w
- Mazanetz, 2020, Ligand- and structure-based drug design and optimization using KNIME, Curr Med Chem, 27, 6458, 10.2174/0929867326666190409141016 · DOI
- Dadi, 2017, SLIMM: species level identification of microorganisms from metagenomes, PeerJ, 5, e3138, 10.7717/peerj.3138 · DOI
- Hong, 2023, Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series, Pharmacotherapy, 43, 291, 10.1002/phar.2786 · DOI
Cited by
The contemporary epidemiology, causes, and management of drug-induced liver injury
Swanson, L., & Fontana, R. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001011
Metadata
- Authors
- Shi, A., Nguyen, H., Kuo, C. B., & Beringer, P. M.
- Venue
- Journal of Cystic Fibrosis
- Publisher
- Elsevier BV
- Published
- 2024-05
- Volume
- 23
- Issue
- 3
- Pages
- 566-572
- ISSN
- 1569-1993
- Cited by
- 36
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 730 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.